According to Zhitong Finance App, Yiming Onko-B (01541) announced that IMC-003/IMM72 (IMC-003, an activin receptor IIA-FC) fusion protein independently developed by the company's subsidiary Yiming Kell Biomedical Technology (Shanghai) Co., Ltd. (Yiming Kell)) has achieved two important clinical milestones.
The phase IB/IIa clinical trial conducted in patients with pulmonary hypertension (PAH) completed the enrollment and administration of the first patient, marking the formal entry of IMC-003 clinical development into the patient verification stage.
The Phase I single dose escalation (SAD) study in healthy postmenopausal women completed enrollment and safety observation period assessments for all dose groups (seven dose groups). IMC-003 was generally well tolerated at a dose level of 8 mg/kg, and no dose-limiting toxicity (DLT) events were reported. The vast majority of all adverse events (AEs) associated with the study drug (IMC 003 or placebo) were grade 1, and no treatment-related AEs of grade 3 or above were reported.
The fourth dose (2 mg/kg) group of the Phase I multiple-dose escalation (MAD) study in healthy postmenopausal women successfully completed enrollment of all eight subjects on August 17, 2026. At this point, all dosage groups designed in the protocol have been enrolled. Early safety data are encouraging: all AEs in the MAD stage were grade 1 or 2, did not report grade 2 or above elevated hemoglobin, and no DLT events occurred in the first three dose groups. The fourth dose group has yet to reach its scheduled safety observation period assessment node.